clinical trials/ BE studies for locally acting drugs [Regulatives / Guidelines]

posted by jagankm  – 2012-01-25 12:26 (5264 d 12:07 ago) – Posting: # 7999
Views: 7,241

Dear Sir/ Madam,

Here we have a query regarding clinical studies of generic products for UK market (Bioequivalence studies). We are developing following generic drug products for UK market:
  1. Docusate sodium 100mg soft gelatin capsules
  2. Sulfasalazine Gastro-resistant Tablets 500 mg
Since both the above drugs are locally acting in gastro intestinal tract. As per the guidelines (CPMP/EWP/QWP/1401/98 Rev. 1/ Corr *, CPMP/EWP/239/95 final), bioequivalence is not a suitable way to show therapeutic equivalence between two products. Could you give a suggestion in showing these two products bioequivalent to innovator products. And is it possible for biowaiver for both the above drug products or any other clinical studies to be conducted to show bioequivalent for these drug products.


Your kind help highly appreciated.

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
124 visitors (0 registered, 124 guests [including 19 identified bots]).
Forum time: 01:33 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution.    Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5